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The increased incidence of multidrug resistance (MDR) and systemic toxicity to 
conventional chemotherapeutic agents suggests that alternative avenues need to be 
explored in the hope of finding new and effective treatments for metastatic disease. 
Considering natural products have made enormous contributions to many of the 
anticancer agents used clinically today, the cytotoxic molluscan metabolite 
tyrindoleninone (1) and its oxidative artifact, 6-bromoisatin (5), were initially used as 
templates for drug design in this study. Structural modifications to the isatin scaffold 
afforded a total of 51 isatin-based analogues, 21 of which were new. Cytotoxicity 
screening of the compounds against a panel of heamatological and epithelial-derived 
cancer cell lines in vitro, found the di- and tri-bromoisatins to be the most potent, with 
activity observed in the low micromolar range. Interestingly compound activity was 
enhanced by up to a factor of 22 after N-alkyl and N-arylalkylation, highlighting the 
importance of N1 substitution for cytotoxic activity. 5,7-Dibromo-N-(p-methylbenzyl)-
isatin (39) was the most active compound overall and exhibited an IC50 value of 490 nM 
against U937 and Jurkat leukemic cell lines, after 24 h. 5,7-Dibromo-N-(p-trifluoro-
methylbenzyl)isatin (54) was also of interest, considering the potent cell killing ability 
displayed against a metastatic breast adenocarcinoma (MDA-MB-231) cell line. 
Investigation into the molecular mode of action of the N-alkylisatin series of 
compounds found the p-trifluoromethylbenzyl derivative (54), together with 9 other 
representative molecules to destabilise microtubules and induce morphological cell 
shape changes via inhibition of tubulin polymerisation. This resulted in cell cycle arrest 
at G2/M and activation of the effector caspases 3 and 7, ultimately resulting in apoptotic 





Further investigations into the pharmacological profile of compound 54 in vivo, found it 
to be moderately efficacious (43% reduction in tumour size compared to vehicle control 
treated mice) in a human breast carcinoma xenograft mouse model. Although 
histopathological analysis of the bone marrow in situ after acute dosing found only mild 
haematopoietic suppression, analysis of biodistribution via SPECT imaging found large 
amounts of activity also in the gut and liver.  
 
In an effort to reduce non-target organ up-take and thus increase accumulation of drug 
in the tumour, the N-benzylisatin 54 was derivatised so as to contain an acid labile 
imine linker and was conjugated to the targeting protein PAI-2 (a naturally occurring 
inhibitor of the urokinase plasminogen activation system) via amide bond formation 
with free lysine residues. The conjugate was found to contain an average of 4 molecules 
of 54 per protein molecule without affecting PAI-2 activity. Hydrolytic stability of the 
PAI-2-cytotoxin conjugate at pH 5-7 as determined by UV/Vis spectrophotometry, was 
directly correlated with the lack of activity observed in vitro, suggesting a need to 
investigate cleavable linker systems with enhanced lability in the future. Despite this, 
PAI-2 conjugated to the cytotoxin 5-FUdr through a succinate linker system, showed 
enhanced and selective uPA-mediated cytotoxicity, in two different breast cancer cell 
lines which varied in their expression levels of uPA and its receptor. This suggests that 
PAI-2-cytotoxin based therapies hold potential, in the future, as new therapeutic agents 
for targeted therapy of uPA positive malignancies, with limited side effects. 
 




ATP adenosine triphosphate 
CDK cyclin-dependant  kinase  
d doublet 
DCC dicyclohexylcarbodiimide 
dd doublet of doublets  
ddd doublet of doublets of doublets 
DMF N,N-dimethylformamide  
DMSO dimethyl sulfoxide 
DNA deoxyribose nucleic acid 
dt doublet of triplets 
EDTA ethylenediaminetriacetic acid 
EI electron impact 
ESI electrospray ionisation 
EtOH ethanol 
FCS foetal calf serum 
HPLC high performance liquid chromatography 
HR high resolution 
HRMS high resolution mass spectrometry 
Hz Hertz 
i.v. intravenous  
J coupling constant 
LDP ligand-directed prodrug  
Lit. literature 
LR low resolution 
m multiplet 
m.p. melting point 
m/z mass to charge ratio 
MDR multi-drug resistance 




MS mass spectrometry 
MTD maximum tolerated dose 
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt 
NHS N-hydroxysuccinamide 
NMR nuclear magnetic resonance  
OD optical density 
p.i. post injection  
PAI-2 plasminogen activator inhibitor type 2 
PBS phosphate buffered saline 
PI propidium iodide 
ppm parts per million 
Rf retention factor 
RME receptor mediated endocytosis 
RPMI-1640 Roswell Park Memorial Institute 
RT room temperature 
s singlet 
SAR structure activity relationship 
SD standard deviation 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM standard error of the mean 
td triplet of doublets 
THF tetrahydrofuran 
TLC thin layer chromatography 
uPA urokinase-type plasminogen activator 
UV/Vis ultraviolet/visible spectrum 
δ chemical shift in ppm downfield form TMS 
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Units Used  
mol mole (6.022 ×1023 particles) 
MW  molecular weight: mass of 1 mole (g/ mole) 
Da Dalton: unit of molecular weight (g/mol) 
g gram 
k kilo (103) 
m milli (10-3) 
μ micro (10-6) 
n nano (10-9) 
L Litre 
M Molar: concentration mole/L 
v/v concentration expressed as volume ratio 




°C degrees Celsius 
K Kelvin 
rpm revolutions per minute 
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